A Meta-analysis Of The Maintenance With Pexetrexed In Advanced Non-small-cell Lung Cancer

Objective:Evaluation of the safety and efficacy of maintenance with pemetrexed in patients with advanced non-small cell lung cancer.Method:The relevant randomized controlled trials (RCT) were searched of several engines,including VIP Datebase, CNKI, PubMed,and The Cochrane Library and manually reviewed the related journals.The related references and experts in this field were traced. Other authors were also communicated with to identify the information that has not been published. Quality of RCTs assessed by the Cochrane Handbook5.01. The RevMan5.01statistical software provided by the Cochrane Collaboration was used to make meta analysis.Results:3RCTs involving1258patients were included. Research suggests the maintenance therapy in patients of the intervent group was superior to the control group for prolonged median progress-survival time (MD＝1.41,95C%CI:0.77,2.04, P<0.00001). The adverse events of maintenance were higher:anemia events (RR=3.1295C%CI,2.03, 4.79, P<0.00001). nausea (RR=3.3895C%CI,2.13,5.35, P<0.00001), diarrhea (RR=1.8495C%CI,0.89,3.81, P=0.1).Conclusion:The maintenance therapy of pemetrexed in advanced non-small-cell lung cancer in the progres-free time was benefit. The benefit of overall surial was slight. Adverse drug reactions than control group, but a low incidence increased tolerated passable; which was the best medicine and who was the most benefit people has not been clearly, need more clinical trials further clear.